Do analysts rate BOLD or GTBP?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Boundless Bio 2 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 GT Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, BOLD or GTBP?

Boundless Bio is trading at a lower price-to-earnings ratio than GT Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Boundless Bio N/A N/A -$58.20M -$2.86 N/A GT Biopharma N/A N/A -$28.35M -$147.50 N/A

Is BOLD or GTBP more profitable?

Boundless Bio's return on equity of -70.89% beat GT Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Boundless Bio N/A -70.89% -47.37% GT Biopharma N/A -213.16% -150.61%

Do analysts rate GTBP or KVAC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GT Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Keen Vision Acquisition 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger earnings & valuation, GTBP or KVAC?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GT Biopharma N/A N/A -$28.35M -$147.50 N/A Keen Vision Acquisition N/A N/A N/A N/A N/A

Is GTBP or KVAC more profitable?

Keen Vision Acquisition's return on equity of 0.00% beat GT Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets GT Biopharma N/A -213.16% -150.61% Keen Vision Acquisition N/A N/A N/A

Do analysts recommend GTBP or INMB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GT Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 INmune Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has higher valuation and earnings, GTBP or INMB?

INmune Bio is trading at a lower price-to-earnings ratio than GT Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GT Biopharma N/A N/A -$28.35M -$147.50 N/A INmune Bio N/A N/A -$45.93M -$0.67 N/A

Is GTBP or INMB more profitable?

INmune Bio's return on equity of -82.87% beat GT Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets GT Biopharma N/A -213.16% -150.61% INmune Bio N/A -82.87% -62.23%

Do analysts prefer RNTX or GTBP?

Rein Therapeutics currently has a consensus target price of $6.00, suggesting a potential upside of 701.07%. Given Rein Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Rein Therapeutics is more favorable than GT Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rein Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 GT Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, RNTX or GTBP?

Rein Therapeutics is trading at a lower price-to-earnings ratio than GT Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Rein Therapeutics N/A N/A -$49.87M -$1.72 N/A GT Biopharma N/A N/A -$28.35M -$147.50 N/A

Is RNTX or GTBP more profitable?

Rein Therapeutics' return on equity of 0.00% beat GT Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Rein Therapeutics N/A N/A -63.69% GT Biopharma N/A -213.16% -150.61%

Do analysts prefer GTBP or EXOZ?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GT Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 eXoZymes 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, GTBP or EXOZ?

eXoZymes is trading at a lower price-to-earnings ratio than GT Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GT Biopharma N/A N/A -$28.35M -$147.50 N/A eXoZymes N/A N/A -$9.16M -$1.19 N/A

Is GTBP or EXOZ more profitable?

GT Biopharma's return on equity of -213.16% beat eXoZymes' return on equity. Company Net Margins Return on Equity Return on Assets GT Biopharma N/A -213.16% -150.61% eXoZymes N/A -292.15% -158.66%

GT Biopharma (GTBP) Competitors

$6.79 -0.31 (-4.42%)

As of 11:48 AM Eastern

Compare

GTBP vs. BOLD, KVAC, INMB, RNTX, and EXOZ

Should you buy GT Biopharma stock or one of its competitors? GT Biopharma's main competitors and comparable companies include Boundless Bio (BOLD), Keen Vision Acquisition (KVAC), INmune Bio (INMB), Rein Therapeutics (RNTX), and eXoZymes (EXOZ). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does GT Biopharma compare to Boundless Bio?

Boundless Bio (NASDAQ:BOLD) and GT Biopharma (NASDAQ:GTBP) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and valuation.

Boundless Bio's return on equity of -70.89% beat GT Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Boundless Bio	N/A	-70.89%	-47.37%
GT Biopharma	N/A	-213.16%	-150.61%

Boundless Bio is trading at a lower price-to-earnings ratio than GT Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Boundless Bio	N/A	N/A	-$58.20M	-$2.86	N/A
GT Biopharma	N/A	N/A	-$28.35M	-$147.50	N/A

In the previous week, GT Biopharma had 1 more articles in the media than Boundless Bio. MarketBeat recorded 1 mentions for GT Biopharma and 0 mentions for Boundless Bio. GT Biopharma's average media sentiment score of 1.78 beat Boundless Bio's score of 0.00 indicating that GT Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Boundless Bio	Neutral
GT Biopharma	Very Positive

Boundless Bio has a beta of -0.03, meaning that its stock price is 103% less volatile than the broader market. Comparatively, GT Biopharma has a beta of 0.91, meaning that its stock price is 9% less volatile than the broader market.

8.2% of GT Biopharma shares are owned by institutional investors. 23.1% of Boundless Bio shares are owned by insiders. Comparatively, 1.2% of GT Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Boundless Bio	2 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
GT Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

GT Biopharma beats Boundless Bio on 6 of the 10 factors compared between the two stocks.

How does GT Biopharma compare to Keen Vision Acquisition?

GT Biopharma (NASDAQ:GTBP) and Keen Vision Acquisition (NASDAQ:KVAC) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, media sentiment, institutional ownership and valuation.

8.2% of GT Biopharma shares are owned by institutional investors. Comparatively, 51.7% of Keen Vision Acquisition shares are owned by institutional investors. 1.2% of GT Biopharma shares are owned by company insiders. Comparatively, 80.2% of Keen Vision Acquisition shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GT Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Keen Vision Acquisition	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Keen Vision Acquisition's return on equity of 0.00% beat GT Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GT Biopharma	N/A	-213.16%	-150.61%
Keen Vision Acquisition	N/A	N/A	N/A

GT Biopharma has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market. Comparatively, Keen Vision Acquisition has a beta of -0.04, suggesting that its stock price is 104% less volatile than the broader market.

In the previous week, GT Biopharma had 1 more articles in the media than Keen Vision Acquisition. MarketBeat recorded 1 mentions for GT Biopharma and 0 mentions for Keen Vision Acquisition. GT Biopharma's average media sentiment score of 1.78 beat Keen Vision Acquisition's score of 0.00 indicating that GT Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
GT Biopharma	Very Positive
Keen Vision Acquisition	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GT Biopharma	N/A	N/A	-$28.35M	-$147.50	N/A
Keen Vision Acquisition	N/A	N/A	N/A	N/A	N/A

Summary

Keen Vision Acquisition beats GT Biopharma on 5 of the 8 factors compared between the two stocks.

How does GT Biopharma compare to INmune Bio?

GT Biopharma (NASDAQ:GTBP) and INmune Bio (NASDAQ:INMB) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings, media sentiment and dividends.

In the previous week, GT Biopharma had 1 more articles in the media than INmune Bio. MarketBeat recorded 1 mentions for GT Biopharma and 0 mentions for INmune Bio. GT Biopharma's average media sentiment score of 1.78 beat INmune Bio's score of 0.00 indicating that GT Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
GT Biopharma	Very Positive
INmune Bio	Neutral

GT Biopharma has a beta of 0.91, indicating that its stock price is 9% less volatile than the broader market. Comparatively, INmune Bio has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GT Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
INmune Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

INmune Bio is trading at a lower price-to-earnings ratio than GT Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GT Biopharma	N/A	N/A	-$28.35M	-$147.50	N/A
INmune Bio	N/A	N/A	-$45.93M	-$0.67	N/A

INmune Bio's return on equity of -82.87% beat GT Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GT Biopharma	N/A	-213.16%	-150.61%
INmune Bio	N/A	-82.87%	-62.23%

8.2% of GT Biopharma shares are held by institutional investors. Comparatively, 12.7% of INmune Bio shares are held by institutional investors. 1.2% of GT Biopharma shares are held by company insiders. Comparatively, 21.4% of INmune Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

INmune Bio beats GT Biopharma on 8 of the 12 factors compared between the two stocks.

How does GT Biopharma compare to Rein Therapeutics?

Rein Therapeutics (NASDAQ:RNTX) and GT Biopharma (NASDAQ:GTBP) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, media sentiment, dividends and analyst recommendations.

Rein Therapeutics' return on equity of 0.00% beat GT Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rein Therapeutics	N/A	N/A	-63.69%
GT Biopharma	N/A	-213.16%	-150.61%

In the previous week, GT Biopharma had 1 more articles in the media than Rein Therapeutics. MarketBeat recorded 1 mentions for GT Biopharma and 0 mentions for Rein Therapeutics. GT Biopharma's average media sentiment score of 1.78 beat Rein Therapeutics' score of 0.00 indicating that GT Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Rein Therapeutics	Neutral
GT Biopharma	Very Positive

90.9% of Rein Therapeutics shares are owned by institutional investors. Comparatively, 8.2% of GT Biopharma shares are owned by institutional investors. 1.5% of Rein Therapeutics shares are owned by insiders. Comparatively, 1.2% of GT Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Rein Therapeutics currently has a consensus target price of $6.00, suggesting a potential upside of 701.07%. Given Rein Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Rein Therapeutics is more favorable than GT Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rein Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
GT Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Rein Therapeutics has a beta of 1.37, meaning that its share price is 37% more volatile than the broader market. Comparatively, GT Biopharma has a beta of 0.91, meaning that its share price is 9% less volatile than the broader market.

Rein Therapeutics is trading at a lower price-to-earnings ratio than GT Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rein Therapeutics	N/A	N/A	-$49.87M	-$1.72	N/A
GT Biopharma	N/A	N/A	-$28.35M	-$147.50	N/A

Summary

Rein Therapeutics beats GT Biopharma on 9 of the 13 factors compared between the two stocks.

How does GT Biopharma compare to eXoZymes?

GT Biopharma (NASDAQ:GTBP) and eXoZymes (NASDAQ:EXOZ) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, media sentiment, institutional ownership and valuation.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GT Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, GT Biopharma had 1 more articles in the media than eXoZymes. MarketBeat recorded 1 mentions for GT Biopharma and 0 mentions for eXoZymes. GT Biopharma's average media sentiment score of 1.78 beat eXoZymes' score of 0.00 indicating that GT Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
GT Biopharma	Very Positive
eXoZymes	Neutral

GT Biopharma's return on equity of -213.16% beat eXoZymes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GT Biopharma	N/A	-213.16%	-150.61%
eXoZymes	N/A	-292.15%	-158.66%

GT Biopharma has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market. Comparatively, eXoZymes has a beta of 3.14, suggesting that its stock price is 214% more volatile than the broader market.

eXoZymes is trading at a lower price-to-earnings ratio than GT Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GT Biopharma	N/A	N/A	-$28.35M	-$147.50	N/A
eXoZymes	N/A	N/A	-$9.16M	-$1.19	N/A

8.2% of GT Biopharma shares are held by institutional investors. 1.2% of GT Biopharma shares are held by company insiders. Comparatively, 72.4% of eXoZymes shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

GT Biopharma beats eXoZymes on 6 of the 10 factors compared between the two stocks.

Get GT Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GTBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GTBP vs. The Competition

Export

Metric	GT Biopharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$12.39M	$3.91B	$7.27B	$13.03B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	-0.05	14.13	274.95	25.63
Price / Sales	N/A	1,446.16	669.16	97.27
Price / Cash	19.20	113.29	77.80	52.76
Price / Book	1.22	15.01	10.32	6.26
Net Income	-$28.35M	-$22.82M	$3.49B	$360.12M
7 Day Performance	-8.08%	-2.72%	-1.33%	-0.42%
1 Month Performance	-9.94%	-7.12%	-3.71%	-3.75%
1 Year Performance	-65.57%	29.24%	14.41%	4.84%

GT Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GTBP GT Biopharma	0.9493 of 5 stars	$6.79 -4.4%	N/A	-65.6%	$12.24M	N/A	N/A	8	Positive News
BOLD Boundless Bio	0.8023 of 5 stars	$2.81 -1.1%	N/A	+134.8%	$63.92M	N/A	N/A	64
KVAC Keen Vision Acquisition	N/A	$11.51 flat	N/A	N/A	$63.37M	N/A	N/A	N/A
INMB INmune Bio	0.2836 of 5 stars	$2.26 -3.0%	N/A	+0.5%	$62.72M	N/A	N/A	10
RNTX Rein Therapeutics	2.4652 of 5 stars	$0.71 -10.6%	$6.00 +748.1%	-31.2%	$61.03M	N/A	N/A	9

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GTBP) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GT Biopharma (GTBP) Competitors

GTBP vs. BOLD, KVAC, INMB, RNTX, and EXOZ

How does GT Biopharma compare to Boundless Bio?

Summary

How does GT Biopharma compare to Keen Vision Acquisition?

Summary

How does GT Biopharma compare to INmune Bio?

Summary

How does GT Biopharma compare to Rein Therapeutics?

Summary

How does GT Biopharma compare to eXoZymes?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GTBP vs. The Competition

GT Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

GT Biopharma (GTBP) Competitors

GTBP vs. BOLD, KVAC, INMB, RNTX, and EXOZ

How does GT Biopharma compare to Boundless Bio?

Is BOLD or GTBP more profitable?

Which has preferable earnings & valuation, BOLD or GTBP?

Does the media prefer BOLD or GTBP?

Which has more volatility and risk, BOLD or GTBP?

Do insiders and institutionals believe in BOLD or GTBP?

Do analysts rate BOLD or GTBP?

Summary

How does GT Biopharma compare to Keen Vision Acquisition?

Do insiders & institutionals believe in GTBP or KVAC?

Do analysts rate GTBP or KVAC?

Is GTBP or KVAC more profitable?

Which has more risk and volatility, GTBP or KVAC?

Does the media favor GTBP or KVAC?

Which has stronger earnings & valuation, GTBP or KVAC?

Summary

How does GT Biopharma compare to INmune Bio?

Does the media favor GTBP or INMB?

Which has more risk and volatility, GTBP or INMB?

Do analysts recommend GTBP or INMB?

Which has higher valuation and earnings, GTBP or INMB?

Is GTBP or INMB more profitable?

Do institutionals and insiders hold more shares of GTBP or INMB?

Summary

How does GT Biopharma compare to Rein Therapeutics?

Is RNTX or GTBP more profitable?

Does the media favor RNTX or GTBP?

Do insiders and institutionals hold more shares of RNTX or GTBP?

Do analysts prefer RNTX or GTBP?

Which has more volatility and risk, RNTX or GTBP?

Which has stronger valuation & earnings, RNTX or GTBP?

Summary

How does GT Biopharma compare to eXoZymes?

Do analysts prefer GTBP or EXOZ?

Does the media prefer GTBP or EXOZ?

Is GTBP or EXOZ more profitable?

Which has more risk and volatility, GTBP or EXOZ?

Which has higher valuation and earnings, GTBP or EXOZ?

Do institutionals and insiders have more ownership in GTBP or EXOZ?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GTBP vs. The Competition

GT Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools